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Although human polyomavirus JC (JCV) is known to cause progressive multifocal leukoencephalopathy (PML) in immunocompromised
individuals, the mechanism by which JCV crosses the blood–brain barrier (BBB) remains unclear. To test our hypothesis that cell-free JCV gains
entry into the brain by infecting endothelial cells, we inoculated human brain microvascular endothelial (HBMVE) cells with 50 HAU (1.33±
0.27×107 genome copies) of JCV(Mad1) and analyzed the expression of early and late viral genes and proteins by immunocytochemistry,
quantitative real-time PCR (qPCR), quantitative real-time reverse transcriptase PCR (qRT-PCR) and immunoprecipitation followed by Western
blotting. JCV infected and replicated efficiently in HBMVE cells and produced infectious virions several hundred fold higher than the infecting
inoculum. HBMVE cells in vitro did not express serotonin receptor 2A (5HT2AR), and 5HT2AR blockers did not prevent JCV infection of
HBMVE cells. Collectively, our data indicate that the productive in vitro infection of HBMVE cells by JCV is independent of 5HT2AR.
© 2007 Elsevier Inc. All rights reserved.Keywords: JCV; Human polyomavirus JC; Polyomaviridae; PML; HIV; AIDS; Blood–brain barrier; HBMVE cells; Human brain microvascular endothelial cells;
Serotonin receptor 2A; 5HT2AR; OligodendrocytesIntroduction
Progressive multifocal leukoencephalopathy (PML), a uni-
formly fatal, subacute demyelinating disease of the central
nervous system (CNS), is caused by human polyomavirus JC
(JCV) (Imperiale, 2001; Mazlo et al., 2001; Padgett et al.,
1977), a member of the family Polyomaviridae, which has a
naked icosahedral capsid and a circular double-stranded DNA
genome of approximately 5.1 kb (Imperiale, 2001; Kim et al.,
2001). Seroepidemiological studies indicate that JCV infects
60–80% of individuals (Knowles et al., 2003). Primary JCV
infection, which is likely acquired via the oral or respiratory
route during childhood, is typically subclinical (Monaco et al.,
1996, 1998). The primary sites of JCV infection and replication
are unknown, although tonsillar tissue has been proposed⁎ Corresponding author. Fax: +1 808 692 1980.
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doi:10.1016/j.virol.2007.02.018(Monaco et al., 1996, 1998). Virus-infected lymphocytes or
cell-free virus presumably spread by the hematogenous route
from the primary site to secondary sites, such as brain and
kidney, to establish focal areas of virus persistence (Monaco et
al., 1996, 1998; Tornatore et al., 1992). JCV persists in the
kidneys, brain, tonsils and lymphocytes of infected individuals,
with or without PML (Dorries et al., 1994; Monaco et al., 1996,
1998; Newman and Frisque, 1999; Tornatore et al., 1992; White
et al., 1992), while pathology is confined to the CNS (Mazlo et
al., 2001; Newman and Frisque, 1999). A neuropathological
hallmark of PML is the destruction of oligodendrocytes, the
myelin-forming cells in the brain, for which JCV has a strong
tropism and which serve as the site of JCV replication in the
brain.
The detection of JCV DNA in the brains of patients with
non-neurological diseases and neurological disorders other than
PML (Elsner and Dorries, 1992; Vago et al., 1996; White et al.,
1992) suggests that immunosuppression is not a prerequisite for
Fig. 1. Primary HBMVE cells in vitro express vWF. (A) Epifluorescence image
demonstrate 90% of HBMVE cells expressing vWF (green) depicted by arrows
and cells lacking vWF expression depicted by arrowheads. The percentage of
vWF-positive cells were quantitated by counting the number of fluorescent cells
in a total of 900 cells selected from three random fields. (B) Immunolabel
control cells stained with secondary antibody only and counterstained with
bisbenzidine for nuclear stain (blue) did not show green fluorescence.
Experiments were performed in duplicate. Scale bars 30 μm.
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brain barrier (BBB) may occur early during the course of
asymptomatic primary infection. Based on the demonstrated
association between JCV and B cells, it has been proposed that
JCV may traffic to the brain via infected B cells (Houff et al.,
1988; Monaco et al., 1996, 1998). JCV has occasionally been
detected in the brain vascular endothelial cells of PML patients
by in situ hybridization (Dorries et al., 1979; von Einsiedel et
al., 2004), and Fareed and colleagues (1978) have suggested
that endothelial cells may support limited JCV replication.
Thus, the most direct method to delineate the mechanism of
JCV transmigration across the BBB is to study the replication
potential of JCV in HBMVE cells, the most critical component
of the BBB. Understanding the mechanisms underlying JCV
trafficking across the BBB may assist in developing preventive
or therapeutic strategies that limit JCV entry into the brain,
resulting in the prevention of JCV persistence in the CNS.
JCV is proposed to initially engage the alpha 2-6-linked sialic
acid receptor (Liu et al., 1998), followed by the interaction with
the serotonin receptor 2A (5HT2AR) (Elphick et al., 2004),
leading to virus internalization into glial cells by clathrin-
dependent endocytosis (Baum et al., 2003). In a recent study,
Elphick and colleagues (2004) demonstrated that several
serotonin receptor antagonists blocked JCV entry and inhibited
JCV infection of glial cells. However, whether such blockers
inhibit JCV trafficking across the BBB is unclear.
We hypothesized that during the viremic phase of asympto-
matic infection, cell-free JCV infects HBMVE cells to cross the
BBB and to establish latency in the brain. During immunosup-
pression, the latent JCV may be activated, resulting in lytic
infection of the oligodendrocytes. In the first step toward
dissecting the migration of JCV across the BBB, we employed
primary HBMVE cells derived from adult brain to demonstrate
replication of JCV(Mad1). Our data indicate that JCV infects
HBMVE cells in vitro, HBMVE cells in vitro do not express
5HT2AR and JCV infection of HBMVE cells is independent of
5HT2AR.
Results
Primary HBMVE cells retain their characteristics
Based on a total of 900 cells counted in three independent
fields, more than 90% of HBMVE cells expressed vWF (Fig.
1A), whereas no vWF was detected in cells stained with only
secondary antibody (Fig. 1B). It has been documented that
HBMVE cells in culture gradually lose vWF expression in
subsequent passages (Mukhtar et al., 2002). It is most likely that
vWF negative cells may represent the subset of HBMVE cells
that have lost their ability to express vWF.
JCV efficiently replicates in HBMVE cells
JCV replication was observed in HBMVE cells. Based on
epifluorescence and confocal microscopy, approximately 15% of
HBMVE cells (vWF stained, green) expressed JCV T antigen
(early protein) at day 10 post-inoculation. Of the total cells, 5%had strong immunoreactivity with anti-SV40 T antigen antibody
which cross-reacts with JCV T antigen (pink color, Fig. 2A),
whereas 10% had moderate immunoreactivity (purple color, Fig.
2A). Multiple nuclei were often observed in JCV-infected cells
(arrowhead to the left, Fig. 2A). No stainingwas observed in JCV-
infected HBMVE cells incubated with only secondary antibodies
(Fig. 2B). Figs. 2C and D show a cluster of four infected cell
nuclei suggesting two subsequent nuclear divisions or fusion of
the infected endothelial cells. Additionally, the infected HBMVE
cells were frequently larger compared to the uninfected cells
(Figs. 2A and D). Although T antigen staining was observed
predominantly in the cell nucleus, we occasionally observed
punctate staining in the cytoplasm of infected cells (Figs. 2E and
F), most probably representing different stages of JCV replication
(von Einsiedel et al., 2004). Moreover, both JCV T antigen (Fig.
2H) and VP-1 (Fig. 2G) proteins were co-localized in the nucleus,
suggesting productive JCV infection (Figs. 2I–J).
Based on the qPCR T antigen (TAg) genome data,
approximately 5% of JCV was attached or internalized into
HBMVE cells at 2 h post-inoculation with 50 HAU of JCV.
There was no difference in the JCV TAg or VP-1 genome copies
recovered from HBMVE cells harvested on days 0 (2 h) and 3
post-inoculation (data not shown). JCV TAg and VP-1 mRNA
transcripts were detected as early as day 3 post-inoculation and
increased exponentially thereafter and paralleled DNA replica-
tion (Figs. 3A–B). On day 20 post-inoculation, the total JCV
TAg (2.72×109) and VP-1 (5.29×109) genome copies recov-
ered from each 35-mm plate were approximately 204- and 395-
Fig. 2. Epifluorescence and confocal microscopy demonstrating presence of JCV T antigen and VP-1. (A) Epifluorescence image demonstrating immunoreactivities
for T antigen (red), vWF (green) and counterstaining for bisbenzidine to visualize cell nuclei (blue) in HBMVE cells infected with 50 HAU of JCV. Several HBMVE
cells display strong immunoreactivity to T antigen in the cell nucleus, as indicated by the pink color (overlap of red and blue colors, arrows). HBMVE cells with
moderate immunoreactivity for T antigen are indicated by the purple color (arrowheads). Note the bi-nucleation in the cell indicated by an arrowhead to the left. (B)
Immunolabel control without primary antibodies with bisbenzidine-counterstained cell nuclei. The secondary antibodies do not show significant background (green or
red colors are not visible). (C) Confocal microscopy image showing four cell nuclei immunoreactive for T antigen (red). (D) The confocal image C, which additionally
displays vWF immunoreactivity, strongly suggests that this infected HBMVE cell (arrow) recently underwent nuclear division or cell fusion. Compare the size of the
infected HBMVE cell with the non-infected HBMVE cell (arrowhead). (E) The presence of T antigen immunoreactivity in both the nucleus (arrow) and cytoplasm
(arrowheads) indicates different stages of viral replication in HBMVE cells. (F) The confocal image E, stained with anti vWF antibody (green). (G–J) JCV-infected
HBMVE cells were simultaneously stained with antibodies against (G) VP-1 (green) and (H) SV-40 T antigen (red). (I) HBMVE cells expressed both VP-1 and T
antigen (arrow) in their nuclei (merged image yellow color). Some JCV-infected cells expressed T antigen in their cytoplasm (arrow in panel H). (J) Triple merged
image with VP-1, T antigen and nuclear staining. Scale bars for A–C and I: 25 μm, and for E: 10 μm.
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Moreover, T antigen protein was detected by immunoprecipita-
tion and Western blot (WB) from JCV-infected HBMVE cells
harvested on days 15 and 20 post-inoculation (Fig. 3C).
Replication profiles of JCV in HBMVE cells and PHFG cells
were very similar (Fig. 3D), suggesting that JCV replication in
HBMVE cells is as efficient as in PHFG cells.
To further verify that JCV infection of HBMVE cells resulted
in production of infectious virions, we inoculated naïve PHFG
cells with HBMVE cell lysates collected at day 20 post-
inoculation and analyzed these for viral DNA and RNA
expression. Our data clearly demonstrated that the virions
produced in HBMVE cell were infectious and JCV produced in
HBMVE cells replicated efficiently in naïve PHFG cells (Figs.
4A and B).JCV infection of HBMVE cells occurs independent of 5HT2AR
Recently, 5HT2AR was reported to be associated with JCV
infection of glial cells (Elphick et al., 2004). Since JCV
replicated efficiently in HBMVE cells, we next examined
whether JCV employs 5HT2AR to infect HBMVE cells.
5HT2AR gene and protein expression was analyzed in
uninfected PHFG, HBMVE and human brain cortical astro-
cytes (HBCA) cells by RT-PCR and WB, respectively. While
PHFG cells expressed 5HT2AR mRNA transcripts (Fig. 5A)
and protein (Fig. 5B), HBMVE and HBCA cells lacked the
expression of 5HT2AR (Figs. 5A and B). Moreover, there was
no significant difference (Fig. 5C) in the JCV replication in
HBMVE cells untreated or exposed continuously to 5-
hydroxytryptamine sulfate (which down regulates serotonin
Fig. 3. JCV replicates in HBMVE cells. HBMVE cells grown in 35-mm plates in
duplicate were infected with JCV(Mad1) for 2 h and viral genome copies and
mRNA transcripts production were monitored over a period of 20 days by qPCR
and qRT-PCR, respectively. (A) Viral genome copies increased rapidly from day
3 to day 20 post-inoculation. (B) JCV TAg and VP-1 mRNA transcripts
increased in parallel with viral genome copies, and (C) JCV T protein was
detected in JCV-infected HBMVE cells by immunoprecipitation and Western
blotting with anti-SV40 T antigen mouse mAb. (D) For comparison, HBMVE
and PHFG cells in 35-mm plates were infected with 50 HAU of JCV, and JCV
TAg genome was quantitated by qPCR. There was no significant difference in
JCV replication in HBMVE and PHFG cells. JCV genome or mRNA transcripts
were expressed as copies per μg DNA or RNA, respectively, and data are
representative of two independent experiments with duplicate samples in each
experiment. Error bars represent SD.
Fig. 4. JCV replication in HBMVE cells produces infectious virions. PHFG cells
grown in 35-mm plates in duplicate were inoculated with day 20 post-
inoculation lysates from JCV-infected HBMVE cells and were analyzed for the
expression of (A) JCV genome and (B) JCV mRNA transcripts. JCV TAg and
VP-1 mRNA transcripts increased in parallel to genome copy numbers.
Fig. 5. HBMVE cells in culture do not express serotonin receptor 2A and
serotonin receptor blockers did not inhibit JCV replication in HBMVE cells.
RNA and total protein were extracted from PHFG, HBMVE and HBCA cells,
lanes 1–3, respectively. (A) cDNAwas synthesized and expression of 5HT2AR
was analyzed by two independent primers (Table 1). Housekeeping gene
GAPDH was used as a positive control. (B) Total cellular protein extract from
PHFG, HBMVE and HBCA cells were analyzed for the expression of 5HT2AR
or housekeeping protein, β-actin by Western blotting using polyclonal 5HT2AR
and monoclonal β-actin antibodies, respectively. (C) JCV replication in
HBMVE cells was quantitated by measuring JCV TAg mRNA transcripts by
qRT-PCR. JCV replication was expressed as percentage of control.
58 M.L. Chapagain et al. / Virology 364 (2007) 55–63receptors), kentaserine (which blocks serotonin receptors 2A
and 2C) or ritanserine (which blocks serotonin receptors 2A,
2B and 2C) (Elphick et al., 2004), suggesting that JCV
infection of HBMVE cells is independent of 5HT2AR.
Discussion
The mechanism of JCV trafficking across the BBB remains
poorly understood. Of the potential pathways, JCV might
employ to cross the BBB, virus-infected B cells have been
proposed (Houff et al., 1988; Monaco et al., 1996, 1998),
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simian immunodeficiency virus (SIV), which gain entry into the
brain via infected monocytes (Trojan horse) (Georgsson, 1994).
However, other potential routes of transmigration of JCV have
not been explored. It is not yet clear whether JCV infects
HBMVE cells productively or latently, like SIV (Mankowski et
al., 1994) and HIV (Liu et al., 2002; Moses et al., 1993),
respectively, to cross the BBB via transcytosis or initially
compromises the BBB and crosses it via the paracellular
pathway. To address this issue, we employed primary HBMVE
cells to study the replication of JCV. We found that JCV
productively infects HBMVE cells in vitro and JCV infection of
HBMVE cells in vitro is independent of 5HT2AR.
Although controversial, available data suggest that JCV can
be detected in the brains of immunocompetent individuals, as
well as in the brains of patients with neurological disorders
other than PML (Elsner and Dorries, 1992; Ferrante et al., 1995;
Vago et al., 1996; White et al., 1992), suggesting that
immunodeficiency is not an absolute prerequisite for migration
of JCVacross the BBB. Instead, JCV may cross the BBB during
asymptomatic primary infection. However, there are no data on
the trafficking of JCV across the BBB. To delineate the
mechanism of JCV transmigration across the BBB, it is
important to study the replication potential of JCV in
HBMVE cells. JCV is well known to have a limited host
range, and productive infection of HBMVE cells has not been
demonstrated. Our data, based on expression of JCV early and
late transcripts by qRT-PCR, T antigen and VP-1 proteins by
immunocytochemistry and T antigen protein by WB, conclu-
sively demonstrate that JCV productively infects HBMVE cells.
Moreover, we demonstrated that the lysates from day 20 JCV-
infected HBMVE cells were infectious in PHFG cells, which
strongly support that infectious JCV virions were produced in
HBMVE cells. Since JCV is known to have a very limited host
range, it was surprising that side-by-side infection of HBMVE
and PHFG cells with the same inoculum size of JCV resulted in
a similar pattern of JCV DNA replication, suggesting that
HBMVE cells may be a suitable alternative to PHFG cells in
future studies on the molecular pathogenesis of PML.
JCV is reported to cause the death of infected oligoden-
drocytes and astrocytes by apoptosis and necrosis, respectively
(Richardson-Burns et al., 2002; Seth et al., 2004). However, we
did not observe any gross or microscopic cytopathic effect in
JCV-infected HBMVE cells in culture, although by immuno-
cytochemistry the infected cells appeared to be slightly larger
than uninfected cells and more often had clusters of nuclei at
day 10 post-inoculation, suggesting more frequent nuclear
division or fusion of JCV-infected HBMVE cells. Polyomavirus
T antigen is a known inducer of S phase (Imperiale, 2001), and
JCV infection may induce S phase progression of HBMVE cells
leading to more frequent nuclear division.
Several viruses, including measles (Andres et al., 2003),
human cytomegalovirus (HCMV) (Fish et al., 1998) and SIV
(Mankowski et al., 1994), are known to productively infect
microvascular endothelial cells in vitro and in vivo. Although
JCV was occasionally detected in the vascular endothelial cells
of PML patients by in situ hybridization (Dorries et al., 1979;von Einsiedel et al., 2004), to our knowledge, this is the first
study demonstrating that JCV can infect and efficiently replicate
in HBMVE cells, the most critical component of the BBB. It is
possible that JCV infection of HBMVE cells in vivo does not
result in productive infection, and the level of antigen expression
is often lower than the detectable threshold. Non-productive
infection or infection in the absence of cytopathology provides
the most favorable environment for establishment of persistent
JCV infection, and HBMVE cells in vivo may be an important
site of JCV latency in immunocompetent individuals.
A recent study demonstrated that the chimera polyomavirus
JC(Mad-1/SVEΔ) consisting of JCV-SV40 promoter–enhancer
sequences in the backbone of JCV coding region sequences
employs the 5HT2AR to infect SVG-A cells, a subclone of
transformed human fetal glial cells by an origin-defective SV40
mutant (Elphick et al., 2004). Antibodies and blockers against
5HT2AR specifically inhibited JCV infection of SVG-A cells,
and insertion of the 5HT2AR gene in receptor-negative and JCV-
resistant HeLa cells restored susceptibility (Elphick et al.,
2004). To our surprise, 5HT2AR blockers did not inhibit JCV
replication in HBMVE cells. Moreover, mRNA and protein
expression data indicated that HBMVE cells in vitro do not
express 5HT2AR, which is consistent with the published
literature (Cohen et al., 1999; Ullmer et al., 1995). This
inconsistency may have resulted from the use of different cell
types. While Elphick et al. (2004) have used SVG-A cells and
JCV chimera (Mad-1/SVEΔ), we employed primary HBMVE
cells and prototype JCV(Mad1), which is predominantly found
among brains of PML patients (Dubois et al., 2001). It is
possible that JCV may employ receptors other than 5HT2AR to
infect HBMVE cells. Interestingly, several viruses, such as HIV
and measles, infect HBMVE cells even though HBMVE cells
do not express known cellular receptors for these viruses
(Andres et al., 2003; Argyris et al., 2003).
At this point, we conjecture that cell-free JCV may cross the
BBB in vivo by infecting HBMVE cells. Our data indicate that
HBMVE cells do not express 5HT2AR, and 5HT2AR blockers
may not prevent the entry of JCV in the brain. Studies are now
underway to delineate the molecular mechanisms of cell-free
JCV transmigration across the in vitro BBB.
Materials and methods
Virus and primary cell cultures
JCV(Mad1) was propagated in primary human fetal glial
(PHFG) cells, purified and quantitated by the HA assay and
real-time PCR (Chapagain et al., 2006), and the transcriptional
control region sequences were reconfirmed by cloning and
sequencing, as described previously (Fernandez-Cobo et al.,
2001).
Low-passage primary HBMVE cells (Cat #ACBRI 376 and
401), isolated from adult human brain cortex and expressing
≥95% vonWillebrand Factor (vWF), were purchased from Cell
Systems Corporation (Kirkland, WA) and propagated on
attachment factor (Cat #4Z0-210) coated T75 flasks with
CSC-Complete medium (Cat #Z0-500) at 37 °C, 5% CO2 and
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experiments were performed with cells between passages 6 and
8. After obtaining approval from the institutional review board
of the Kapi'olani Medical Center for Women and Children,
Honolulu, Hawaii, PHFG cells were isolated from therapeuti-
cally aborted 10- to 14-week-old fetal brains, as described
previously (Chapagain et al., 2006; Padgett et al., 1977).
Characterization of HBMVE cells
Cultured HBMVE cells grown on coverslips were washed
twice with 1× PBS and fixed in 4% paraformaldehyde. After
permeabilization with 0.5% Triton X-100 and pre-incubation in
PBS–0.2% gelatin, HBMVE cells were incubated at room
temperature with primary rabbit polyclonal antibody against
vWF (1:500 dilution) (Cat #ab6994, Abcam, Cambridge, MA)
for 2 h, washed and incubated with fluorescein isothiocyanate
(FITC)-conjugated donkey anti-rabbit (1:100) (Cat #N1034V,
Amersham, Pittsburgh, PA) secondary antibody for 40 min,
followed by three washes with PBS. Cells were counterstained
with 2 μg/mL bisbenzidine (Cat #H33258, Sigma Aldrich, St.
Louis, MO) for 5 min to visualize cell nuclei and mounted with
Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA). Fluorescent cells were examined using a Zeiss
Confocal Pascal equipped with a Zeiss Axiovert 200 micro-
scope, or an Axiocam MRm camera mounted on a Zeiss
Axiovert 200 microscope, both equipped with appropriate
fluorescence filters and objectives.
JCV infection of HBMVE cells
On each attachment factor-coated 35-mm culture plate, 105
HBMVE cells were seeded and grown to 70–80% confluency
and inoculated with 50 HAU containing approximately 1.33±
0.27×107 genome copies of JCV(Mad1). After adsorption for
2 h, the medium was aspirated; plates were washed three times
with 1× PBS and then incubated with 2mL of fresh medium. The
medium was changed every 2 days, and cells were harvested for
DNA, RNA and protein extraction on days 3, 5, 10, 15 and 20
post-inoculation. For comparison, PHFG cells seeded on 35-mm
plates were inoculated with the same dose (50 HAU) of
prototype JCV(Mad1), and cells were harvested and DNA was
extracted at the same time points post-inoculation, as mentioned
above. Additionally, for enumerating the number of T antigen
expressing cells, HBMVE cells were grown on attachment
factor-coated coverslips, infected with 50 HAU of JCV and on
day 10 post-inoculation, fixed and permeabilized as described
above. The coverslips were stained with anti-vWF antibody (see
above) and mouse monoclonal anti-SV40 Tantigen (1:400) (Cat
#DP02, EMD Biosciences, San Diego, CA), which cross reacts
with JCV Tantigen protein, for 2 h at room temperature, washed
and incubated with biotinylated anti-mouse IgG from sheep (Cat
# RPN 1001, Amersham, 1:250) and FITC-conjugated donkey
anti-rabbit (Cat #RPN1034, Amersham, 1:250) for 40 min,
washed and further incubated for 40 min with streptavidin–
Texas red (1:250) (Cat #RPN1233, Amersham, Buckingham-
shire, England). Moreover, JCV-infected HBMVE cells weresimultaneously incubated with mouse monoclonal antibody
against SV-40 and rabbit polyclonal anti-VP-1 antibody
(1:1500) (Chang et al., 1996) for 2 h, washed and incubated
with secondary antibodies as above. Finally, the cells were
counterstained with bisbenzidine for visualizing cell nuclei, and
fluorescent cells were visualized with epifluorescence or
confocal microscopy as described above.
DNA and RNA extraction
Uninfected and JCV-infected HBMVE cells in 35-mm plates
were washed twice with 1× PBS and were either frozen for
DNA extraction or lysed with 350 μL of RLT plus buffer (Cat
#74134, Qiagen) for RNA extraction and stored at −80 °C.
100 μL of DNA was extracted with the Qiagen QIAprep Spin
Miniprep Kit (Cat #27104) from each 35-mm plate, according
to the manufacturer's protocol. Cells lysed with RLT plus buffer
were thawed, homogenized by passing through a QIAshredder
spin column (Cat #79654) and 50 μL RNA was extracted with
RNeasy Plus kit (Cat #74134, Qiagen). Genomic DNA was
eliminated by employing gDNA eliminator column and by
treating the RNA in the spin column with DNase (Cat #79254,
Qiagen) for 30 min.
Quantitation of viral DNA and mRNA
JCV DNA or cDNA synthesized from 0.5 μg total RNAwith
Bio-Rad's iScript cDNA synthesis kit (Bio-Rad Inc., Hercules,
CA) were amplified and quantitated in the Bio-Rad iCycler iQ
Multicolor Real-Time PCR Detection System using 2 μL of
template DNA/cDNA, Bio-Rad 2× iQ SYBER Green supermix
and 12.5 pmol each of forward and reverse primers specific for
JCV TAg (Chapagain et al., 2006; Ryschkewitsch et al., 2004)
and VP-1 genes (Table 1), in a final reaction volume of 20 μL.
Thermal cycling conditions are outlined in Table 1 (Chapagain et
al., 2006; Ryschkewitsch et al., 2004). Real-time PCR
amplification data were analyzed using the Bio-Rad iCycler iQ
Multicolor Real-Time PCR Optical System Software Version
3.1. A standard curve for the quantitation of JCV was
constructed using serial dilutions of the linearized JCV(Mad1)
plasmid. The dynamic range of detection was determined by
preparing 10-fold serial dilutions of JCV plasmid DNA (pDNA)
in the range of 1.0×106 to 1.0×101 copies of JCV pDNA in each
PCR template. All experiments were repeated at least twice and
each sample was processed in duplicate. Copies of JCV genome
or cDNA (mRNA transcript) in experimental samples were
calculated from the standard curve and were expressed as copies
of viral genome or mRNA transcript in one μg of DNA or RNA
respectively. The reliability of qPCR and qRT-PCR was defined
by calculating coefficients of variation (Ct) values of replicates
of standard curve dilutions (Chapagain et al., 2006).
Immunoprecipitation and Western immunoblot for detection of
JCV T antigen
HBMVE cells infected with 200 HAU of JCV(Mad1) in each
100-mm plate were washed twice with cold PBS and lysed with
Table 1
Primer sequences and cycling conditions
Target gene (GenBank
accession no.)
Nucleotide
position
Primer sequence (5′–3′) Amplicon
size
PCR cycling conditions
JCV (J02226)
JCV TAg (F) a 4298–4320 AGA GTG TTG GGATCC TGT GTT TT 78 bp 95 °C 4 min; 95 °C 10 s, 60 °C 30 s, 40 cycles;
JCV TAg (R) a 4375–4352 GAG AAG TGG GAT GAA GAC CTG TTT 55 °C to 95 °C 10 s, 80 cycles b
JCV VP-1 (F) a 1853–1875 CAT GAC AAT GGT GCA GGG AAG CC 180 bp 95 °C 4 min; 95 °C 10 s, 58 °C 30 s, 40 cycles;
JCV VP-1 (R) a 2032–2012 CGC CTT GTG CTC TGT GTT CAT 55 °C to 95 °C 10 s, 80 cycles b
5HT2AR (NM_000621)
5HT2AR-1 (F)
c 951–970 GGC ACA CGG GCC AAATTA GC 141 bp 95 °C 4 min; 90 °C 20 s, 58 °C 20 s, 72 °C 30s;
5HT2AR-1 (R)
c 1091–1070 TTG CTC ATT GCT GAT GGA CTG C 35 cycles; 72 °C 10 min
5HT2AR-2 (F)
c 793–817 AGG TCT TTA AGG AGG GGA GTT GCT T 301 bp 95 °C 90 s; 95 °C 30 s, 68 °C 60 s, 45 cycles;
5HT2AR-2 (R)
c 1093–1071 TTT TGC TCA TTG CTG ATG GAC TG 68 °C 10 min
GAPDH (BC025925)
GAPDH (F)a,c 5–26 AGT TAG CCG CAT CTT CTT TTG C 96 bp 95 °C 4 min; 90 °C 20 s, 58 °C 20 s, 72 °C 30 s,
GAPDH (R)a,c 100–78 CAA TAC GAC CAA ATC CGT TGA CT 35 cycles; 72 °C 10 min
a Real-time PCR primers for quantitating JCV and GAPDH.
b Melt curve.
c RT-PCR primers for 5HT2AR and GAPDH.
61M.L. Chapagain et al. / Virology 364 (2007) 55–63500 μL NP40 lysis buffer, consisting of 50 mM Tris pH 7.5,
120 mM NaCl, 0.5% NP-40 and 1% protease inhibitor cocktail
(Cat #P8340, Sigma-Aldrich) (Tyagarajan and Frisque, 2006).
Total cellular protein was separated by centrifuging the lysate for
30 min at 10,000×g at 4 °C. Protein concentration was
determined by the Bradford technique (Bio-Rad), and T antigen
from 250 μg of total protein extracts was immunoprecipitated
using 60 μL of Protein G Plus/Protein A Agarose suspension
(Cat #IP05) and 10 μL (2 μg) of anti-SV40 T antigen mouse
mAb (Cat #DP02, EMD Biosciences, San Diego, CA), which
recognizes JCV T antigen protein, and incubated overnight at
4 °C. The suspension was then spun down, washed three times in
resuspension buffer, dissolved in sample buffer (NuPAGE 10%
reducing buffer and 4× loading dye, Cat #NP0007, Invitrogen)
and was heated at 95 °C for 10 min. In order to separate out the
beads, the suspension was centrifuged at 10,000×g for 5 min and
20 μL of supernatant was fractionated on 4–12%NuPAGE Bis–
Tris gradient gels (Cat #NP0322, Invitrogen). Proteins were
transferred by electroblotting onto nitrocellulose filters (Cat
#162-0112, Bio-Rad) and blocked for 2 h in 10% skim milk in
1× PBS with 0.1% Tween (PBST). Filters were incubated
overnight at 4 °C with anti-SV40 T antigen mouse primary
antibody (1:1,000 dilution), washed three times with PBST for
30 min and incubated with goat alkaline phosphatase (AP)-
conjugated anti-mouse IgG secondary antibody (1:3,000 dilu-
tion) for 2 h at room temperature. After three vigorous washes
with PBST, the membranes were developed using a color
development kit (Cat #170-6532, Bio-Rad).
Effect of serotonin blockers on JCV infection of HBMVE cells
HBMVE cells in 35-mm plates in duplicate were first
incubated for 1 h with either medium alone or medium
containing 5-hydroxytryptamine sulfate (1.0 μM), kentaserine
(0.1 μM) or ritanserine (0.1 μM) (Sigma-Aldrich) (Elphick et
al., 2004) and inoculated with JCV in the continuous presenceof each drug. JCV TAg mRNA transcript copies detected in
drug-treated JCV-infected HBMVE cells were expressed as
percentage of JCV-infected drug naïve HBMVE cells in 35-mm
plates.
Detection of 5HT2AR expression by RT-PCR
RNA was extracted from HBMVE, HBCA and PHFG cells
and 1 μg of RNAwas employed for cDNA synthesis. 5HT2AR
gene was amplified using two independent primer pairs
5HT2AR-1 and 5HT2AR-2 (Table 1) in a GeneAmp Thermal
Cycler 9700 (Perkin-Elmer, Wellesley, MA) with 4 μL of cDNA
in a 20-μL reaction mixture containing 0.5 U AmpliTaq Gold
(Applied Biosystems, Foster City, CA), PCR buffer with
1.5 mM MgCl2, 0.2 mM dNTPs and 0.4 μM of each primer.
Thermal cycling conditions are outlined in Table 1 (Verheggen
et al., 2004). Simultaneously, PCR was performed using primers
specific for housekeeping gene GAPDH (Table 1), which was
used as an internal control. The amplicons were electrophoresed
on a 2% agarose gel, and the ethidium bromide fluorescence was
visualized after scanning with a Bio-Rad Molecular Phosphor-
imager. Additionally, amplicons were gel purified using Qiagen
Gel Purification Kit (Qiagen) according to the manufacturer's
instructions and directly sequenced in both directions using
PCR primers on an automated sequencer (Model 373A, Applied
Biosystems, Foster City, CA). Based on the NCBI Genomic
BLAST program, the 254-bp amplicon sequence was identical
to the 5HT2AR sequence deposited in the GenBank (accession
number NM_000621) (data not shown).
Detection of 5HT2AR expression by Western immunoblot
Total cellular protein extract (40 μg), fractioned on a 4–12%
gradient SDS polyacrylamide gel, was transferred onto 0.2-μm
nitrocellulose filters (Bio-Rad) and non-specific binding sites
were blocked with 5% skim milk in 1× PBS–Tween (0.05%).
62 M.L. Chapagain et al. / Virology 364 (2007) 55–63Membranes were further incubated with anti-5HT2AR mouse
polyclonal antibody (1 μg/mL) (Cat #556236, BD Pharmingen™,
San Diego, CA) or 1:5,000 diluted mouse anti-β-actin
monoclonal antibody (Cat #A5316, Sigma-Aldrich) overnight
at 4 °C, followed by incubation with AP-conjugated goat anti-
mouse IgG antibody (Cat #170-6520, Bio-Rad) for 2 h at room
temperature and developed with AP-conjugate substrate kit
(Bio-Rad).
Acknowledgments
This work was supported by U.S. Public Health Service
grants from the Collaborative Neurological Sciences Program
(S11 NS041833) and the Specialized Neuroscience Research
Program (U54 NS039406), the National Institute of Neurolo-
gical Disorders and Stroke, as well as from the Research Centers
in Minority Institutions Program (G12 RR003061) and the
Centers of Biomedical Research Excellence (P20 RR018727),
National Center for Research Resources, National Institutes of
Health.
We thank Dr. Deching Chang and Dr. Richard Frisque for the
generous gift of VP-1 antibody and JCV(Mad1), respectively.
We also thank Dr. Frisque for critical comments on a previous
version of this manuscript, Dr. Satoru Arai and the Greenwood
Molecular Biology Facility, UHM, for sequencing. Ms. Juliene
Co, Ms. Ushii Gurjav, Ms. Laarni Sumibicay, Ms. Yeung Lo
and the staff and students of the Retrovirology Research
Laboratory provided technical assistance.
References
Andres, O., Obojes, K., Kim, K.S., ter Meulen, V., Schneider-Schaulies, J.,
2003. CD46- and CD150-independent endothelial cell infection with wild-
type measles viruses. J. Gen. Virol. 84 (Pt. 5), 1189–1197.
Argyris, E.G., Acheampong, E., Nunnari, G., Mukhtar, M., Williams, K.J.,
Pomerantz, R.J., 2003. Human immunodeficiency virus type 1 enters
primary human brain microvascular endothelial cells by a mechanism
involving cell surface proteoglycans independent of lipid rafts. J. Virol. 77
(22), 12140–12151.
Baum, S., Ashok, A., Gee, G., Dimitrova, S., Querbes, W., Jordan, J., Atwood,
W.J., 2003. Early events in the life cycle of JC virus as potential
therapeutic targets for the treatment of progressive multifocal leukoence-
phalopathy. J. Neurovirol. 9 (Suppl. 1), 32–37.
Chang, D., Liou, Z.M., Ou, W.C., Wang, K.Z., Wang, M., Fung, C.Y., Tsai, R.T.,
1996. Production of the antigen and the antibody of the JC virus major
capsid protein VP1. J. Virol. Methods 59 (1–2), 177–187.
Chapagain, M.L., Nguyen, T., Bui, T., Verma, S., Nerurkar, V.R., 2006.
Comparison of real-time PCR and hemagglutination assay for quantitation
of human polyomavirus JC. Virol. J. 3, 3.
Cohen, Z., Bouchelet, I., Olivier, A., Villemure, J.G., Ball, R., Stanimirovic,
D.B., Hamel, E., 1999. Multiple microvascular and astroglial 5-hydro-
xytryptamine receptor subtypes in human brain: molecular and pharmaco-
logic characterization. J. Cereb. Blood Flow. Metab. 19 (8), 908–917.
Dorries, K., Johnson, R.T., ter Meulen, V., 1979. Detection of polyoma virus
DNA in PML-brain tissue by (in situ) hybridization. J. Gen. Virol. 42 (1),
49–57.
Dorries, K., Vogel, E., Gunther, S., Czub, S., 1994. Infection of human
polyomaviruses JC and BK in peripheral blood leukocytes from immuno-
competent individuals. Virology 198 (1), 59–70.
Dubois, V., Moret, H., Lafon, M.E., Brodard, V., Icart, J., Ruffault, A.,
Guist'hau, O., Buffet-Janvresse, C., Abbed, K., Dussaix, E., Ingrand, D.,
2001. JC virus genotypes in France: molecular epidemiology and potentialsignificance for progressive multifocal leukoencephalopathy. J. Infect. Dis.
183 (2), 213–217.
Elphick, G.F., Querbes, W., Jordan, J.A., Gee, G.V., Eash, S., Manley, K.,
Dugan, A., Stanifer, M., Bhatnagar, A., Kroeze, W.K., Roth, B.L., Atwood,
W.J., 2004. The human polyomavirus, JCV, uses serotonin receptors to
infect cells. Science 306 (5700), 1380–1383.
Elsner, C., Dorries, K., 1992. Evidence of human polyomavirus BK and JC
infection in normal brain tissue. Virology 191 (1), 72–80.
Fareed, G.C., Takemoto, K.K., Gimbrone Jr., M.A., 1978. Interaction of simian
virus 40 and human papovaviruses, BK and JC, with human vascular
endothelial cells. In: Schlessinger, D. (Ed.), Microbiology. American
Society of Microbiology, Washington, DC, pp. 427–431.
Fernandez-Cobo, M., Jobes, D.V., Yanagihara, R., Nerurkar, V.R., Yamamura,
Y., Ryschkewitsch, C.F., Stoner, G.L., 2001. Reconstructing population
history using JC virus: Amerinds, Spanish, and Africans in the ancestry of
modern Puerto Ricans. Hum. Biol. 73 (3), 385–402.
Ferrante, P., Caldarelli-Stefano, R., Omodeo-Zorini, E., Vago, L., Boldorini,
R., Costanzi, G., 1995. PCR detection of JC virus DNA in brain tissue
from patients with and without progressive multifocal leukoencephalo-
pathy. J. Med. Virol. 47 (3), 219–225.
Fish, K.N., Soderberg-Naucler, C., Mills, L.K., Stenglein, S., Nelson, J.A.,
1998. Human cytomegalovirus persistently infects aortic endothelial cells.
J. Virol. 72 (7), 5661–5668.
Georgsson, G., 1994. Neuropathologic aspects of lentiviral infections. Ann.
N. Y. Acad. Sci. 724, 50–67.
Houff, S.A., Major, E.O., Katz, D.A., Kufta, C.V., Sever, J.L., Pittaluga, S.,
Roberts, J.R., Gitt, J., Saini, N., Lux, W., 1988. Involvement of JC virus-
infected mononuclear cells from the bone marrow and spleen in the
pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J.
Med. 318 (5), 301–305.
Imperiale, M.J., 2001. The human polyomaviruses: an overview. In: Khalili, K.,
Stoner, G.L. (Eds.), Human Polyomaviruses Molecular and Clinical
Perspectives. Wiley-Liss Inc., New York, pp. 53–71.
Kim, H.-S., Henson, J.W., Frisque, R.J., 2001. Transcription and replication in
the human polyomaviruses. In: Khalili, K., Stoner, G.L. (Eds.), Human
Polyomaviruses. Wiley-Liss Inc., New York, pp. 73–126.
Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W.,
Miller, E., 2003. Population-based study of antibody to the human
polyomaviruses BKV and JCV and the simian polyomavirus SV40.
J. Med. Virol. 71 (1), 115–123.
Liu, C.K., Wei, G., Atwood, W.J., 1998. Infection of glial cells by the human
polyomavirus JC is mediated by an N-linked glycoprotein containing
terminal alpha(2-6)-linked sialic acids. J. Virol. 72 (6), 4643–4649.
Liu, N.Q., Lossinsky, A.S., Popik, W., Li, X., Gujuluva, C., Kriederman, B.,
Roberts, J., Pushkarsky, T., Bukrinsky, M., Witte, M., Weinand, M., Fiala,
M., 2002. Human immunodeficiency virus type 1 enters brain microvascular
endothelia by macropinocytosis dependent on lipid rafts and the mitogen-
activated protein kinase signaling pathway. J. Virol. 76 (13), 6689–6700.
Mankowski, J.L., Spelman, J.P., Ressetar, H.G., Strandberg, J.D., Laterra,
J., Carter, D.L., Clements, J.E., Zink, M.C., 1994. Neurovirulent
simian immunodeficiency virus replicates productively in endothelial
cells of the central nervous system in vivo and in vitro. J. Virol. 68
(12), 8202–8208.
Mazlo, M., Ressetar, H.G., Stoner, G.L., 2001. The neuropathology and
pathogenesis of progressive multifocal leukoencephalopathy. In: Khalili, K.,
Stoner, G.L. (Eds.), Human Polyomaviruses, Molecular and Clinical
Perspectives. Wiley-Liss Inc., New York, pp. 257–335.
Monaco, M.C., Atwood, W.J., Gravell, M., Tornatore, C.S., Major, E.O., 1996.
JC virus infection of hematopoietic progenitor cells, primary B lymphocytes,
and tonsillar stromal cells: implications for viral latency. J. Virol. 70 (10),
7004–7012.
Monaco, M.C., Jensen, P.N., Hou, J., Durham, L.C., Major, E.O., 1998.
Detection of JC virus DNA in human tonsil tissue: evidence for site of initial
viral infection. J. Virol. 72 (12), 9918–9923.
Moses, A.V., Bloom, F.E., Pauza, C.D., Nelson, J.A., 1993. Human
immunodeficiency virus infection of human brain capillary endothelial
cells occurs via a CD4/galactosylceramide-independent mechanism.
Proc. Natl. Acad. Sci. U.S.A. 90 (22), 10474–10478.
63M.L. Chapagain et al. / Virology 364 (2007) 55–63Mukhtar, M., Harley, S., Chen, P., BouHamdan, M., Patel, C., Acheampong, E.,
Pomerantz, R.J., 2002. Primary isolated human brain microvascular
endothelial cells express diverse HIV/SIV-associated chemokine coreceptors
and DC-SIGN and L-SIGN. Virology 297 (1), 78–88.
Newman, J.T., Frisque, R.J., 1999. Identification of JC virus variants in
multiple tissues of pediatric and adult PML patients. J. Med. Virol. 58 (1),
79–86.
Padgett, B.L., Rogers, C.M., Walker, D.L., 1977. JC virus, a human
polyomavirus associated with progressive multifocal leukoencephalopathy:
additional biological characteristics and antigenic relationships. Infect.
Immun. 15 (2), 656–662.
Richardson-Burns, S.M., Kleinschmidt-DeMasters, B.K., DeBiasi, R.L., Tyler,
K.L., 2002. Progressive multifocal leukoencephalopathy and apoptosis of
infected oligodendrocytes in the central nervous system of patients with and
without AIDS. Arch. Neurol. 59 (12), 1930–1936.
Ryschkewitsch, C., Jensen, P., Hou, J., Fahle, G., Fischer, S., Major, E.O., 2004.
Comparison of PCR-southern hybridization and quantitative real-time PCR
for the detection of JC and BK viral nucleotide sequences in urine and
cerebrospinal fluid. J. Virol. Methods 121 (2), 217–221.
Seth, P., Diaz, F., Tao-Cheng, J.H., Major, E.O., 2004. JC virus induces
nonapoptotic cell death of human central nervous system progenitor cell-
derived astrocytes. J. Virol. 78 (9), 4884–4891.
Tornatore, C., Berger, J.R., Houff, S.A., Curfman, B., Meyers, K., Winfield, D.,
Major, E.O., 1992. Detection of JC virus DNA in peripheral lymphocytesfrom patients with and without progressive multifocal leukoencephalopathy.
Ann. Neurol. 31 (4), 454–462.
Tyagarajan, S.K., Frisque, R.J., 2006. Stability and function of JC virus large T
antigen and T′ proteins are altered by mutation of their phosphorylated
threonine 125 residues. J. Virol. 80 (5), 2083–2091.
Ullmer, C., Schmuck, K., Kalkman, H.O., Lubbert, H., 1995. Expression of
serotonin receptor mRNAs in blood vessels. FEBS Lett. 370 (3), 215–221.
Vago, L., Cinque, P., Sala, E., Nebuloni, M., Caldarelli, R., Racca, S., Ferrante,
P., Trabottoni, G., Costanzi, G., 1996. JCV-DNA and BKV-DNA in the CNS
tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and
review of the literature. J. Acquir. Immune Defic. Syndr. Human Retrovirol.
12 (2), 139–146.
Verheggen, R., Meier, A., Werner, I., Wienekamp, A., Kruschat, T., Brattelid, T.,
Levy, F.O., Kaumann, A., 2004. Functional 5-HT receptors in human
occipital artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (4),
391–401.
von Einsiedel, R.W., Samorei, I.W., Pawlita, M., Zwissler, B., Deubel, M.,
Vinters, H.V., 2004. New JC virus infection patterns by in situ polymerase
chain reaction in brains of acquired immunodeficiency syndrome patients
with progressive multifocal leukoencephalopathy. J. Neurovirol. 10 (1),
1–11.
White III, F.A., Ishaq, M., Stoner, G.L., Frisque, R.J., 1992. JC virus DNA is
present in many human brain samples from patients without progressive
multifocal leukoencephalopathy. J. Virol. 66 (10), 5726–5734.
